-
Merck Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment and Sustained E Phase IV studies demonstrate the consistent safety and high efficacy of MAVENCLAD on NEDA-3, MRI and cognition outcomes over four years New data on blood and CSF biomarkers show the impact of MAVE...资讯2024-09-13 -
-
-
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharma ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-445...资讯2024-09-13
-
-
-
-
-
-
-
-
最热
推荐
- 望京留创园承接第九期凤凰学院，打造朝阳区顶级商学院
- 庆祝国庆75周年 中华春节符号十岁庆典与微电影首映在广州盛大开启
- Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
- 爱可声助听器亮相第7届成都国际养老服务业博览会暨福祉嘉年华
- 甜蜜加乘，心动满「氛」 BVLGARI宝格丽香氛挚献 520浪漫爱礼
- 智能引领 比翼齐飞丨商越智能采购平台R6「双子座」正式发布！
- Lifezone Metals完成5000万美元无担保可转换债券的私募
- 啤酒与创新ICT的「发酵」效应：酒业巨头智赢工业数字化未来
- AACSB Announces 2024 Class of Influential Leaders
- “蓬勃计划”国际创投大会终评大会在广州举办